Abstract: A system for micro-segmented networking is provided. A system controller is programmed to a) store a plurality of micro-segmented network accounts and a plurality of subscriber accounts, b) receive a request from a user device to activate a first micro-segmented network associated with a first subscriber account, c) authenticate the first subscriber account based on the subscriber information, d) activate the first micro-segmented network, including a plurality of device slots for a plurality of devices, e) transmit, to the user device, first device slot authentication information for a first device slot of the plurality of device slots; f) receive, from a first device connecting to the wireless network, the first device slot authentication information; g) authenticate the first device slot authentication information; and h) in response to authenticating the first device slot authentication information, connect the first device to the first micro-segmented network.

Abstract: A logic puzzle having a shaped game space with edges defining an overall shape, within which are included a plurality of shaped subsets, each having an equal multiplicity of subdivided segments or cells that collectively provide for a preliminary solution set and a final solution set, with the final solution set realized when each of the shaped subsets includes a preliminary solution set and when the preliminary solution set is also formed in a predetermined pattern across multiple shaped subsets.

Abstract: A three-dimensional logic puzzle having a multiplicity of face sides wherein a final solution set is provided by forming a preliminary solution set on each of the face sides and across the face sides in a predetermined pattern.

Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.